Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
Published May 7, 2025: https://doi.org/10.1093/eurheartj/ehaf314
Obesity rates have surged since 1990 worldwide. This rise is paralleled by increases in pathological processes affecting organs such as the heart, liver, and kidneys, here termed systemic metabolic disorders (SMDs).
For clinical management of SMD, the European Atherosclerosis Society proposes a pathophysiology-based system comprising three stages:
| Stage 1 | Metabolic abnormalities such as dysfunctional adiposity and dyslipidaemia occur without detectable organ damage |
| Stage 2 | Involves early organ damage manifested as Type 2 diabetes, asymptomatic diastolic dysfunction, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD) |
| Stage 3 | Characterized by more advanced organ damage affecting multiple organs. Various forms of high-risk obesity, driven by maintained positive energy balance, are the most common cause of SMD, leading to ectopic lipid accumulation and insulin resistance. This progression affects various organs, promoting comorbidities such as hypertension and atherogenic dyslipidaemia. |
Genetic factors influence SMD susceptibility, and ethnic disparities in SMD are attributable to genetic and socio-economic factors. Key SMD features include insulin resistance, inflammation, pre-diabetes, Type 2 diabetes, MASH, hypertension, CKD, atherogenic dyslipidaemia, and heart failure.
Management strategies involve lifestyle changes, pharmacotherapy, and metabolic surgery in severe cases, with emerging treatments focusing on genetic approaches.
The staging system provides a structured approach to understanding and addressing the multi-faceted nature of SMD, which is crucial for improving health outcomes. Categorization of SMD abnormalities by presence and progression is aimed to improve awareness of a multi-system trait and encourage a tailored and global approach to treatment, ultimately aiming to reduce the burden of obesity-related comorbidities.
Hear from Co-Chairs Prof Stefano Romeo (Sweden), Prof Antonio Vidal-Puig (UK), and Prof Mansoor Husain (Canada) as they share their insights and perspectives.